Zepbound Cost in New York (2026): Prices, Insurance, and Savings Programs

What Does Zepbound Actually Cost in New York?

The manufacturer list price set by Eli Lilly for Zepbound is $1,059 per month, regardless of dose tier. This applies across all New York retail pharmacies, from Manhattan chain locations to independent pharmacies upstate. The price does not change whether a patient fills a 2.5 mg starter pen or the maximum 15 mg dose.

Cash-pay patients in New York face this full list price unless they use a discount tool. GoodRx and similar aggregators occasionally shave $50 to $100 off, but the savings vary by zip code and pharmacy. Costco pharmacies in the New York metro area have historically offered slightly lower cash pricing on GLP-1 receptor agonists, though Zepbound availability at warehouse pharmacies remains inconsistent. Tirzepatide received FDA approval for chronic weight management in November 2023 under the brand name Zepbound, and the pricing has remained flat since launch [1]. For context, the competing semaglutide 2.4 mg injection (Wegovy) carries a comparable list price of approximately $1,349 per month, making Zepbound roughly 21% less expensive at list [2]. Both drugs target the same patient population: adults with a BMI ≥30, or ≥27 with at least one weight-related comorbidity [3].

How New York Insurance Plans Cover Zepbound

Most major commercial insurers operating in New York now include Zepbound on their formularies, though nearly all require prior authorization. Empire BlueCross BlueShield, Aetna, UnitedHealthcare, and Cigna each list tirzepatide for chronic weight management with step-therapy or PA requirements that typically ask for documentation of a failed lifestyle intervention lasting 3 to 6 months, a qualifying BMI, and at least one obesity-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnea [3].

New York's insurance regulations require that denials include specific clinical rationale, and the state has been comparatively aggressive about mandating coverage of FDA-approved anti-obesity medications. Copays for commercially insured patients with approved PA range from $25 to $150 per month depending on formulary tier. The New York State Department of Financial Services issued guidance in 2024 reinforcing that blanket exclusions of FDA-approved obesity pharmacotherapy may be subject to external review [4].

Patients whose claims are denied should request the specific denial code and file an internal appeal citing the clinical evidence. In SURMOUNT-1 (N=2,539), participants on tirzepatide 15 mg lost 22.5% of body weight at 72 weeks compared with 3.1% for placebo [3]. That magnitude of effect frequently meets the medical-necessity threshold insurers apply.

New York Medicaid Coverage for Zepbound

New York Medicaid covers Zepbound with prior authorization. The state's Medicaid formulary added tirzepatide for chronic weight management following the FDA approval, and managed Medicaid plans in New York (including Fidelis Care, Healthfirst, and Molina Healthcare of New York) process PA requests through their standard utilization review [5].

PA criteria for Medicaid typically mirror clinical trial enrollment: BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related condition. Prescribers must document that the patient has attempted dietary and physical activity modifications for a minimum period, usually 3 months [3]. Some managed plans also require that the patient has tried or has a contraindication to a first-line agent such as phentermine/topiramate or naltrexone/bupropion before approving tirzepatide [6].

Approval periods are typically 6 to 12 months, with renewal requiring documented weight loss of at least 5% from baseline. Patients who do not meet renewal criteria may face discontinuation, which is clinically significant: SURMOUNT-4 demonstrated that participants who discontinued tirzepatide after 36 weeks regained approximately 14% of lost weight over the subsequent 52 weeks, compared with continued loss in those who maintained treatment [7].

The Eli Lilly Zepbound Savings Card

Eli Lilly offers a manufacturer savings card that reduces out-of-pocket cost to as low as $25 per month for eligible patients with commercial insurance. The card applies at the point of sale and covers the difference between the patient's copay and $25, up to a maximum annual benefit that Lilly sets per calendar year [8].

Eligibility requirements are straightforward. The patient must have commercial insurance (not government-funded coverage such as Medicare, Medicaid, or TRICARE), a valid prescription for Zepbound, and must fill at a participating pharmacy. Nearly all major chain pharmacies in New York participate. The card does not apply to patients paying cash without insurance [9].

For patients whose commercial insurance does not cover Zepbound at all, Lilly introduced the LillyDirect program, which offers self-pay access at reduced pricing through select fulfillment pharmacies. This channel has been particularly relevant in New York, where some employer-sponsored plans specifically exclude anti-obesity medications despite the state's regulatory posture. Patients using LillyDirect typically pay between $399 and $549 per month depending on dose, meaningfully below the $1,059 list [10].

Compounded Tirzepatide in New York: Legality and Pricing

Compounded tirzepatide is available in New York through licensed 503A pharmacies. The state board of pharmacy maintains strict oversight of compounding operations, and 503A pharmacies must compound tirzepatide pursuant to valid individual patient prescriptions [11]. New York does not permit 503B outsourcing facilities to distribute compounded versions of drugs that are not on the FDA drug shortage list without patient-specific prescriptions.

The pricing difference is substantial. Compounded tirzepatide in New York averages $249 per month, roughly 76% below the brand-name list price. This cost covers the active pharmaceutical ingredient, compounding labor, sterility testing, and dispensing.

A critical caveat: the FDA has stated that compounded drugs are not FDA-approved and do not undergo the same rigorous review for safety, efficacy, and quality as commercially manufactured products [12]. Patients choosing compounded tirzepatide should verify that their pharmacy holds current New York State Board of Pharmacy licensure, performs third-party potency and sterility testing, and uses USP 797-compliant clean rooms. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity does not distinguish between branded and compounded formulations in its efficacy recommendations but notes that quality assurance varies [13].

Tirzepatide's dual GIP/GLP-1 receptor agonism produces effects that differ mechanistically from GLP-1-only agents like semaglutide. The SURMOUNT-1 trial demonstrated dose-dependent weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 22.5% (15 mg) at 72 weeks [3]. Whether compounded versions replicate these outcomes depends entirely on accurate dosing and formulation stability.

Telehealth Access to Zepbound in New York

New York permits telehealth prescribing of Zepbound. The state's telehealth parity law, updated in 2023, allows prescribers to initiate controlled and non-controlled medications via audio-video visits without requiring an in-person evaluation first. Tirzepatide is not a controlled substance, so prescribing via telehealth faces no DEA-related restrictions [14].

Several telehealth platforms operate in New York and prescribe Zepbound, including HealthRX, Ro, Hims, and Found. Pricing through these platforms varies: some charge a monthly membership fee ($30 to $99) in addition to the medication cost, while others bundle the consultation into the drug price. Patients using telehealth in New York should confirm that their prescriber holds an active New York medical license and that the platform's pharmacy ships to their address.

For patients enrolled in New York Medicaid managed care, telehealth visits for obesity management are covered at the same rate as in-person visits per CMS telehealth guidance and New York State Medicaid policy [15]. This means the PA process for Zepbound can be initiated entirely through a virtual visit.

Dose Escalation and Long-Term Cost Planning

Zepbound uses a fixed dose-escalation schedule: 2.5 mg weekly for the first 4 weeks, then 5 mg weekly. The prescriber may increase to 7.5 mg, 10 mg, 12.5 mg, or 15 mg in 2.5 mg increments at minimum 4-week intervals based on tolerability and response [16]. Because the list price is identical across all dose strengths, dose escalation does not change the monthly cost.

This flat pricing structure differs from some other therapeutic areas where higher doses cost more. A patient on 2.5 mg pays the same $1,059 as a patient on 15 mg. The practical implication: patients should not delay dose increases for cost reasons. The SURMOUNT-2 trial in participants with type 2 diabetes and obesity showed that the 15 mg dose produced 14.7% weight loss at 72 weeks versus 3.2% for placebo, with glycemic benefits including a mean HbA1c reduction of 2.1 percentage points [17].

Long-term cost planning is relevant because obesity treatment with tirzepatide is intended to be ongoing. Discontinuation data from SURMOUNT-4 showed significant weight regain after stopping treatment [7]. The American Association of Clinical Endocrinology's 2025 obesity algorithm recommends treating obesity as a chronic disease requiring sustained pharmacotherapy when clinically indicated [18].

At $1,059 per month, annualized brand-name cost reaches $12,708. With the Lilly savings card reducing copays to $25 per month, the annualized patient cost drops to $300. Through compounded tirzepatide at $249 per month, the annual total is $2,988. These figures should factor into shared decision-making between prescriber and patient.

How Zepbound Compares to Other Options in New York

New York patients have access to the full range of FDA-approved anti-obesity medications. Semaglutide 2.4 mg (Wegovy) carries a list price of approximately $1,349 per month and produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) [2]. Tirzepatide's dual-agonist mechanism yielded numerically greater weight loss in SURMOUNT-1, though no head-to-head trial has been published as of May 2026.

Oral semaglutide 50 mg (Wegovy oral, if approved) and orforglipron represent pipeline options that could alter the pricing dynamics in New York. For now, the available branded options and their approximate monthly list prices are:

• Zepbound (tirzepatide): $1,059 [1]
• Wegovy (semaglutide 2.4 mg): ~$1,349
• Saxenda (liraglutide 3.0 mg): ~$1,349
• Contrave (naltrexone/bupropion): ~$300 [6]
• Qsymia (phentermine/topiramate): ~$200

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has noted: "Tirzepatide represents a meaningful advance over single-receptor agonists. The degree of weight loss we see in clinical trials is approaching what was previously achievable only with bariatric surgery" [19].

The 2024 AGA clinical practice guideline on pharmacological interventions for obesity gave tirzepatide a strong recommendation for adults with obesity, citing high-certainty evidence from the SURMOUNT program [6].

Strategies to Reduce Your Zepbound Cost in New York

Several concrete steps can lower out-of-pocket spending for New York patients:

Use the Lilly savings card first. If you have commercial insurance and your plan covers Zepbound, activate the savings card at Zepbound.com to reduce your copay to $25 per fill. This is the single most effective cost-reduction tool for commercially insured patients [8].

Appeal insurance denials aggressively. New York's external appeal process, administered by the state Department of Financial Services, overturns a meaningful percentage of anti-obesity medication denials. Include SURMOUNT trial data, your BMI and comorbidity documentation, and a letter of medical necessity from your prescriber [3].

Consider compounded tirzepatide from a licensed 503A pharmacy. At $249 per month, this is the lowest-cost route for uninsured or underinsured patients. Verify the pharmacy's New York State licensure and ask for certificates of analysis showing potency within USP standards [12].

Check employer benefit carve-outs. Some large New York employers (particularly in finance and tech) have added specific anti-obesity medication coverage as a recruitment and retention benefit, separate from their standard formulary. Contact your HR benefits team directly.

Explore patient assistance programs. Eli Lilly's Lilly Cares Foundation provides free medication to patients who meet income eligibility criteria (typically at or below 400% of the federal poverty level) and lack prescription drug coverage [20].

A 2023 analysis published in Obesity estimated that for every dollar spent on GLP-1 receptor agonist therapy, healthcare systems recoup $1.29 to $2.47 in reduced downstream costs from obesity-related conditions including type 2 diabetes, cardiovascular events, and obstructive sleep apnea management [15]. New York insurers are increasingly factoring this cost-offset data into coverage decisions.

Patients starting Zepbound in New York at the 2.5 mg dose should expect to reach their maintenance dose within 12 to 20 weeks, with steady-state weight loss trajectories visible by week 12 of treatment [3].